Department of Radiology, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkhla, 90110, Thailand.
BMC Gastroenterol. 2021 Nov 8;21(1):419. doi: 10.1186/s12876-021-02004-z.
Inoperable hepatocellular carcinoma (HCC) is treated by conventional transarterial chemoembolization (cTACE) using cone-beam computed tomography (CBCT) or digital subtraction angiography (DSA). We compared patient survival outcomes between CBCT-cTACE with automated tumor-feeder detection (AFD) software and DSA-cTACE alone in inoperable HCC patients.
We reviewed the data of 337 HCC patients treated by CBCT-cTACE or DSA-cTACE between January 2015 and December 2019. Treatment response, progression-free survival (PFS), overall survival (OS), and complications between the CBCT-cTACE and DSA-cTACE groups were compared. Univariate and multivariate logistic regression analyses examined the potential prognostic factors affecting survival after chemoembolization.
Tumor response rates in complete response, partial response, and stable disease at 1 month were 67%, 28%, and 4% in the CBCT-cTACE group and 22%, 48%, and 9% in the DSA-cTACE group, respectively. OS rates of patients in the CBCT-cTACE versus DSA-cTACE groups were 87% versus 54%, 44% versus 15%, and 34% versus 7% at 1, 3, and 5 years, respectively. The CBCT-cTACE group had significantly improved PFS (p < 0.001) and OS (p < 0.001). Multivariate analysis showed that CBCT with AFD software was an independent factor associated with longer OS (hazard ratio, 0.38; p < 0.001).
Compared with conventional DSA, combining selective cTACE with CBCT and AFD software leads to better tumor response and prolongs OS in patients with inoperable HCC.
无法手术的肝细胞癌(HCC)采用锥形束 CT(CBCT)或数字减影血管造影(DSA)的常规经动脉化疗栓塞(cTACE)治疗。我们比较了无法手术的 HCC 患者中 CBCT-cTACE 联合自动肿瘤供血动脉检测(AFD)软件与单纯 DSA-cTACE 的患者生存结局。
我们回顾了 2015 年 1 月至 2019 年 12 月期间接受 CBCT-cTACE 或 DSA-cTACE 治疗的 337 例 HCC 患者的数据。比较 CBCT-cTACE 与 DSA-cTACE 组的治疗反应、无进展生存期(PFS)、总生存期(OS)和并发症。单因素和多因素逻辑回归分析检查了影响化疗栓塞后生存的潜在预后因素。
CBCT-cTACE 组 1 个月时完全缓解、部分缓解和稳定疾病的肿瘤反应率分别为 67%、28%和 4%,DSA-cTACE 组分别为 22%、48%和 9%。CBCT-cTACE 组与 DSA-cTACE 组的 OS 率分别为 87%比 54%、44%比 15%、34%比 7%,1、3 和 5 年时。CBCT-cTACE 组具有显著改善的 PFS(p<0.001)和 OS(p<0.001)。多因素分析显示,CBCT 联合 AFD 软件是与更长 OS 相关的独立因素(风险比,0.38;p<0.001)。
与传统 DSA 相比,选择性 cTACE 联合 CBCT 和 AFD 软件可提高无法手术 HCC 患者的肿瘤反应率并延长 OS。